---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-296814"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:48:05.042176+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Syndax announces $200M public offering of common stock at $18.50/share

## Summary
- Issued 10,810,810 shares at $18.50; gross proceeds ~$200M ($230M with overallotment).
- Underwriters: Goldman Sachs, J.P. Morgan, Cowen and Company; deal expected to close Dec. 19, 2023.
- Lock-up agreement: company, directors, officers, certain stockholders restricted for 60 days.
- Offering made under existing S-3 shelf registration (File 333-254661).

## SEC filing metadata
- accession: 0001193125-23-296814
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312523296814/0001193125-23-296814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312523296814/d50500d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-296814
- JSON: https://secwatch.observer/filing/0001193125-23-296814.json
- Plain text: https://secwatch.observer/filing/0001193125-23-296814.txt

## Key facts
- Material Agreements
  Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $200.0 million (effective 2023-12-14).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters
  - Value: approximately $200.0 million
  - Effective: 2023-12-14
  source text: On December 14, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 10,810,810 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a price to the public of $18.50 per share (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000119312523296814/0001193125-23-296814-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.